2026 Update on the Management of Diffuse Large B-Cell Lymphoma - PubMed
3 months ago
- #immunotherapy
- #DLBCL
- #lymphoma
- Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere.
- R-CHP remains the backbone of therapy, with frontline options including pola-R-CHP and R-CHOP for fit patients, and R-mini-CHOP or palliation for elderly/frail patients.
- Frontline trials focus on improving outcomes for high-risk patients using R-CHOP combined with novel agents, CAR-T, and bispecific antibodies.
- Risk-adapted approaches targeting cell of origin (COO) and utilizing interim PET imaging or ctDNA are under investigation.
- Second-line curative-intent therapies include CAR-T or autologous stem cell transplantation, depending on disease progression timing.
- Relapsed/refractory DLBCL treatments have expanded, including bispecific antibody combinations, antibody-drug conjugates, and targeted therapies.
- Ongoing trials aim to reduce chemotherapy reliance, exploring targeted therapy-antibody combinations, immunomodulatory agents, and cellular therapies.